<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35384774</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chitosan-coated bovine serum albumin nanoparticles for topical tetrandrine delivery in glaucoma: <i>in vitro</i> and <i>in vivo</i> assessment.</ArticleTitle>
        <Pagination>
          <StartPage>1150</StartPage>
          <EndPage>1163</EndPage>
          <MedlinePgn>1150-1163</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2058648</ELocationID>
        <Abstract>
          <AbstractText>Glaucoma is one of the leading causes of blindness. Therapies available suffer from several drawbacks including low bioavailability, repeated administration and poor patient compliance with adverse effects thereafter. In this study, bovine serum albumin nanoparticles (BSA-NPs) coated with chitosan(CS) were developed for the topical delivery of tetrandrine (TET) for glaucoma management. Optimized nanoparticles were prepared by desolvation. pH, BSA, CS and cross-linking agent concentrations effects on BSA-NPs colloidal properties were investigated. CS-BSA-NPs with particle size 237.9 nm and zeta potential 24 mV was selected for further evaluation. EE% exceeded 95% with sustained release profile. In vitro mucoadhesion was evaluated based on changes in viscosity and zeta potential upon incubation with mucin. <i>Ex vivo</i> transcorneal permeation was significantly enhanced for CS coated formulation. <i>In vitro</i> cell culture studies on corneal stromal fibroblasts revealed NPs biocompatibility with enhanced cellular uptake and improved antioxidant and anti-proliferative properties for the CS-coated formulation. Moreover, BSA-NPs were nonirritant as shown by HET-CAM test. Also, bioavailability in rabbit aqueous humor showed 2-fold increase for CS-TET-BSA-NPs compared to TET with a sustained reduction in intraocular pressure in a rabbit glaucoma model. Overall, results suggest CS-BSA-NPs as a promising platform for topical ocular TET delivery in the management of glaucoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Radwan</LastName>
            <ForeName>Salma El-Sayed</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>El-Moslemany</LastName>
            <ForeName>Riham M</ForeName>
            <Initials>RM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mehanna</LastName>
            <ForeName>Radwa A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Physiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Research in Regenerative Medicine and Applications (CERRMA), Faculty of Medicine, Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thabet</LastName>
            <ForeName>Eman H</ForeName>
            <Initials>EH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Physiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Research in Regenerative Medicine and Applications (CERRMA), Faculty of Medicine, Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdelfattah</LastName>
            <ForeName>Elsayeda-Zeinab A</ForeName>
            <Initials>EA</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute (MRI), Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>El-Kamel</LastName>
            <ForeName>Amal</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044182">Benzylisoquinolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>27432CM55Q</RegistryNumber>
          <NameOfSubstance UI="D012710">Serum Albumin, Bovine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>29EX23D5AJ</RegistryNumber>
          <NameOfSubstance UI="C009438">tetrandrine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9012-76-4</RegistryNumber>
          <NameOfSubstance UI="D048271">Chitosan</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044182" MajorTopicYN="N">Benzylisoquinolines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048271" MajorTopicYN="Y">Chitosan</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005901" MajorTopicYN="Y">Glaucoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012710" MajorTopicYN="N">Serum Albumin, Bovine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Tetrandrine</Keyword>
        <Keyword MajorTopicYN="N">albumin nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">chitosan</Keyword>
        <Keyword MajorTopicYN="N">glaucoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35384774</ArticleId>
        <ArticleId IdType="pmc">PMC9004496</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2058648</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abdelmonem R, Elhabal SF, Abdelmalak NS, et al.  (2021). Formulation and characterization of acetazolamide/carvedilol niosomal gel for glaucoma treatment: in vitro, and in vivo study. Pharmaceutics
13:1–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7915822</ArticleId>
            <ArticleId IdType="pubmed">33562785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal P, Huang D, Thakur SS, Rupenthal ID. (2018). Chapter 4 – Nanotechnology for ocular drug delivery. Des Nanostruct Versatile Ther Appl
137–88.</Citation>
        </Reference>
        <Reference>
          <Citation>Akhter S, Ramazani F, Ahmad MZ, et al.  (2013). Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits. Eur J Nanomedicine
5:159–67.</Citation>
        </Reference>
        <Reference>
          <Citation>Akman A, Cetinkaya A, Akova YA, Ertan A. (2005). Comparison of additional intraocular pressure-lowering effects latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye
19:145–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15184958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarado HL, Abrego G, Garduño-Ramirez ML, et al.  (2015). Design and optimization of oleanolic/ursolic acid-loaded nanoplatforms for ocular anti-inflammatory applications. Nanomed Nanotechnol Biol Med
11:521–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25659643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An F, Zhang X. (2017). Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics
7:3667–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667340</ArticleId>
            <ArticleId IdType="pubmed">29109768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordeiro S, Silva B, Martins AM, et al.  (2021). Antioxidant‐loaded mucoadhesive nanoparticles for eye drug delivery: a new strategy to reduce oxidative stress. Processes
9:1–19.</Citation>
        </Reference>
        <Reference>
          <Citation>Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci
13:123–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11297896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cueto AFV, Álvarez L, García M, et al.  (2021). H. González-iglesias, candidate glaucoma biomarkers: from proteins to metabolites, and the pitfalls to clinical applications. Biology (Basel)
10:1–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8389649</ArticleId>
            <ArticleId IdType="pubmed">34439995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Redín IL, Boiero C, Martínez-Ohárriz MC, et al.  (2018). Human serum albumin nanoparticles for ocular delivery of bevacizumab. Int J Pharm 541:214–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29481946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elzoghby AO, Samy WM, Elgindy NA. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release
157:168–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21839127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engin KN, Yemişci B, Yiğit U, et al.  (2010). Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients. Mol Vis
16:1260–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2903467</ArticleId>
            <ArticleId IdType="pubmed">20664701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfandyari-Manesh M, Mohammadi A, Atyabi F, et al.  (2016). Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer. Int J Pharm
515:607–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27989825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fellows MD, O'Donovan MR. (2007). Cytotoxicity in cultured mammalian cells is a function of the method used to estimate it. Mutagenesis
22:275–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17456508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galisteo-González F, Molina-Bolívar JA. (2014). Systematic study on the preparation of BSA nanoparticles. Colloids Surf B Biointerfaces
123:286–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25262407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gharge V, Pawar P. (2017). Recent trends in chitosan based nanotechnology: a reference to ocular drug delivery system. Int J Ophthalmol Visual Sci 2:98–105.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang P, Xu Y, Wei R, et al.  (2011). Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension. J Glaucoma
20:183–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20440217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalam MA. (2016). The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone. Int J Biol Macromol
89:559–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27164496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karimi M, Avci P, Mobasseri R, et al.  (2013). The novel albumin-chitosan core-shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation. J. Nanoparticle Res
15:1651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3868460</ArticleId>
            <ArticleId IdType="pubmed">24363607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karimi M, Bahrami S, Ravari SB, et al.  (2016). Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv
13:1609–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5063715</ArticleId>
            <ArticleId IdType="pubmed">27216915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalaf AM, El-moslemany RM, Ahmed MF, et al.  (2022). Exploring a novel fasudil-phospholipid complex formulated as liposomal thermosensitive in situ gel for glaucoma. Int J Nanomedicine
17:163–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8760977</ArticleId>
            <ArticleId IdType="pubmed">35046652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D, Maharjan P, Jin M, et al.  (2019). Potential albumin-based antioxidant nanoformulations for ocular protection against oxidative stress. Pharmaceutics
11:297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6680573</ArticleId>
            <ArticleId IdType="pubmed">31248013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumara BN, Shambhu R, Prasad KS. (2021). Why chitosan could be apt candidate for glaucoma drug delivery - an overview. Int J Biol Macromol
176:47–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33581206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanier OL, Manfre MG, Bailey C, et al.  (2021). Review of approaches for increasing ophthalmic bioavailability for eye drop formulations. AAPS PharmSciTech
22:107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33719019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Guo X, Liu Z, et al.  (2014). Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies. Drug Dev Ind Pharm
40:980–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23662696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Jin X, Zhang L, et al.  (2020). Comparison of different chitosan lipid nanoparticles for improved ophthalmic tetrandrine delivery: formulation, characterization, pharmacokinetic and molecular dynamics simulation. J Pharm Sci
109:3625–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32946897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Tian S, Tao Q, et al.  (2018). Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma. Int J Nanomedicine
13:3975–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6045908</ArticleId>
            <ArticleId IdType="pubmed">30022821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Yang C, Lu J, et al.  (2014). Tetrandrine protects mouse retinal ganglion cells from ischemic injury. Drug Des Dev Ther
8:327–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3968085</ArticleId>
            <ArticleId IdType="pubmed">24711693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Song H, Xiong S, et al.  (2018). Chitosan-stablized bovine serum albumin nanoparticles having ability to control the release of NELL-1 protein. Int J Biol Macromol
109:672–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29288032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu R, Wang S, Fang S, et al.  (2016). Liquid crystalline nanoparticles as an ophthalmic delivery system for tetrandrine: development, characterization, and in vitro and in vivo evaluation. Nanoscale Res Lett
11:11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4870510</ArticleId>
            <ArticleId IdType="pubmed">27188974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu XG, Zhang RX, Fu F, et al.  (2015). Simultaneous determination of fangchinoline and tetrandrine in Qi-Fang-Xi-Bi-Granules by RP-HPLC. J Chromatogr Sci
53:1328–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25754692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Y, Teng Z, Li Y, Wang Q. (2015). Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr Polym
122:221–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25817662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcondes N, Fernandes F, Faulhaber G. (2018). Ki-67 expression in mature B-cell neoplasms: a flow cytometry study. Rev Assoc Med Bras
64:525–29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30304310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marty JJ, Oppenheim RC, Speiser P. (1978). Nanoparticles–a new colloidal drug delivery system. Pharm Acta Helv
53:17–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">643885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittal N, Kaur G. (2019). Leucaena leucocephala (Lam.) galactomannan nanoparticles: optimization and characterization for ocular delivery in glaucoma treatment. Int J Biol Macromol
139:1252–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31419555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad-Beigi H, Shojaosadati SA, Morshedi D, et al.  (2016). The effects of organic solvents on the physicochemical properties of human serum albumin nanoparticles. Iran J Biotechnol
14:45–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5435013</ArticleId>
            <ArticleId IdType="pubmed">28959317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mun EA, Morrison PWJ, Williams AC, Khutoryanskiy VV. (2014). On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein. Mol Pharm
11:3556–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25165886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagarwal RC, Singh PN, Kant S, et al.  (2011). Chitosan nanoparticles of 5-fluorouracil for ophthalmic dlivery: characterization, in-vitro and in-vivo study. Chem Pharm Bull (Tokyo)
59:272–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21297311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagymihaly RM, Moe MC, Petrovski G. (2020). Isolation and culture of corneal stromal stem cells. Methods Mol. Biol 214:1–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32542596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nath M, Halder N, Velpandian T. (2017). Circulating biomarkers in glaucoma, age-related macular degeneration, and diabetic retinopathy. Indian J Ophthalmol
65:191–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5426123</ArticleId>
            <ArticleId IdType="pubmed">28440247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Occhiutto ML, Maranhão RC, Costa VP, Konstas AG. (2020). Nanotechnology for medical and surgical glaucoma therapy—a review. Adv Ther
37:155–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6979457</ArticleId>
            <ArticleId IdType="pubmed">31823205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oglesby EN, Tezel G, Cone-Kimball E, et al.  (2016). Scleral fibroblast response to experimental glaucoma in mice. Mol Vis
22:82–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4734151</ArticleId>
            <ArticleId IdType="pubmed">26900327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Öztürk AA, Namlı İ, Güleç K, Kıyan HT. (2020). Diclofenac sodium loaded PLGA nanoparticles for inflammatory diseases with high anti-inflammatory properties at low dose: formulation, characterization and in vivo HET-CAM analysis. Microvasc Res
130:103991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32105668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pahuja P, Arora S, Pawar P. (2012). Ocular drug delivery system: a reference to natural polymers. Expert Opin Drug Deliv
9:837–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22703523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parra A, Mallandrich M, Clares B, et al.  (2015). Design and elaboration of freeze-dried PLGA nanoparticles for the transcorneal permeation of carprofen: ocular anti-inflammatory applications. Colloids Surf B Biointerfaces
136:935–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26551871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parveen S, Sahoo SK. (2011). Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol
670:372–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21951969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piazzini V, Landucci E, D'Ambrosio M, et al.  (2019). Chitosan coated human serum albumin nanoparticles: a promising strategy for nose-to-brain drug delivery. Int J Biol Macromol
129:267–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30726749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitha I, Oglesby E, Chow A, et al.  (2018). Rho-kinase inhibition reduces myofibroblast differentiation and proliferation of scleral fibroblasts induced by transforming growth factor β and experimental glaucoma. Transl Vis Sci Technol
7:6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6238981</ArticleId>
            <ArticleId IdType="pubmed">30479877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radwan SE-S, El-Kamel A, Zaki EI, et al.  (2021). Hyaluronic-coated albumin nanoparticles for the non-invasive delivery of apatinib in diabetic retinopathy. Int J Nanomedicine
16:4481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8259843</ArticleId>
            <ArticleId IdType="pubmed">34239300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radwan SES, Sokar MS, Abdelmonsif DA, El-Kamel AH. (2017). Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: in vitro and in vivo evaluation/sub-acute toxicity study. Int J Pharm
526:366–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28487189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahul T, Sethiya NK, Gulbake AS, et al.  (2021). A review on albumin as a biomaterial for ocular drug delivery. Int J Biol Macromol
191:591–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34562538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raj R, Wairkar S, Sridhar V, Gaud R. (2018). Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol
109:27–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29247729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrigues CM, Alves TFR, Klensporf-pawlik D, et al.  (2020). Nanopharmaceuticals for eye administration: sterilization, depyrogenation and clinical applications. Biology (Basel)
9:336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7602230</ArticleId>
            <ArticleId IdType="pubmed">33066555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi S, Ferrari F, Bonferoni MC, Caramella C. (2000). Characterization of chitosan hydrochloride-mucin interaction by means of viscosimetric and turbidimetric measurements. Eur J Pharm Sci
10:251–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10838014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi S, Ferrari F, Bonferoni MC, Caramella C. (2001). Characterization of chitosan hydrochloride-mucin rheological interaction: influence of polymer concentration and polymer:mucin weight ratio. Eur J Pharm Sci
12:479–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11231115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-López E, Egea MA, Davis BM, et al.  (2018). Memantine-loaded PEGylated biodegradable nanoparticles for the treatment of glaucoma. Small
14:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29154484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satheshkumar S. (2005). Ketamine – xylazine anaesthesia in rabbits. Indian Vet J
82:388–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Satoh K, Butler WL. (1978). Low temperature spectral properties of subchloroplast fractions purified from spinach. Plant Physiol
61:373–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1091871</ArticleId>
            <ArticleId IdType="pubmed">16660296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva MM, Calado R, Marto J, et al.  (2017). Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration. Mar Drugs
15:1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5742830</ArticleId>
            <ArticleId IdType="pubmed">29194378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh M, Guzman-aranguez A, Hussain A, et al.  (2019). Solid lipid nanoparticles for ocular delivery of isoniazid: evaluation, proof of concept and in vivo safety &amp; kinetics. Nanomedicine (Lond)
14:465–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30694726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonntag T, Froemel F, Stamer WD, et al.  (2021). Distribution of gold nanoparticles in the anterior chamber of the eye after intracameral injection for glaucoma therapy. Pharmaceutics
13:1–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8235414</ArticleId>
            <ArticleId IdType="pubmed">34204364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan YL, Ho HK. (2018). Navigating albumin-based nanoparticles through various drug delivery routes. Drug Discov Today
23:1108–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29408437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tara M, Abdullah A. (2016). Chondroitin sulfate-chitosan nanoparticles for ocular delivery of bromfenac sodium: improved permeation, retention, and penetration. Int J Pharm Investig
6:96–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4797493</ArticleId>
            <ArticleId IdType="pubmed">27051629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thongborisute J, Takeuchi H. (2008). Evaluation of mucoadhesiveness of polymers by BIACORE method and mucin-particle method. Int J Pharm
354:204–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18207675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Chen S, Yang X, et al.  (2021). Preparation optimization of bovine serum albumin nanoparticles and its application for sirna delivery. Drug Des Dev Ther
15:1531–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8053787</ArticleId>
            <ArticleId IdType="pubmed">33883877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Li P, Kong L. (2013). Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech
14:585–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3665987</ArticleId>
            <ArticleId IdType="pubmed">23463262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiaoyan A, Jun Y, Min W, et al.  (2008). Preparation of chitosan-gelatin scaffold containing tetrandrine-loaded nano-aggregates and its controlled release behavior. Int J Pharm
350:257–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17945449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young I. (2001). Measurement of total antioxidant capacity. J Clin Pathol
54:356–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1731414</ArticleId>
            <ArticleId IdType="pubmed">11328833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Jiao J, Niu M, et al.  (2021). Ten years of knowledge of nano-carrier based drug delivery systems in ophthalmology: current evidence, challenges, and future prospective. Int J Nanomedicine
16:6497–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8473849</ArticleId>
            <ArticleId IdType="pubmed">34588777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Huo M, Zhou J, et al.  (2010). DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. Aaps J
12:263–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2895453</ArticleId>
            <ArticleId IdType="pubmed">20373062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Huo M, Zhou J, Xie S. (2010). PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed
99:306–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20176408</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
